Clinical Trial Update: Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trials evaluated the efficacy and safety of oral bosentan for pulmonary fibrosis associated with systemic sclerosis, and the studies have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Systemic Sclerosis

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Fibrosis, Scleroderma, Systemic | Phase 2, Phase 3 | Status: COMPLETED